Charles Schwab Investment Management Inc. Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Charles Schwab Investment Management Inc. raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 11.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 130,143,942 shares of the biopharmaceutical company's stock after purchasing an additional 12,864,343 shares during the period. Pfizer accounts for 0.7% of Charles Schwab Investment Management Inc.'s investment portfolio, making the stock its 26th biggest position. Charles Schwab Investment Management Inc. owned about 2.30% of Pfizer worth $3,766,366,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of PFE. Olistico Wealth LLC bought a new stake in shares of Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter worth $29,000. Gladius Capital Management LP lifted its holdings in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 38,015 shares during the last quarter. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter worth $31,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Pfizer during the 2nd quarter worth $34,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 target price on the stock. Barclays lifted their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research report on Wednesday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average target price of $32.92.

Insider Buying and Selling

In other news, Director Scott Gottlieb bought 1,000 shares of the company's stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Trading Up 0.5 %

Shares of NYSE PFE traded up $0.12 during midday trading on Thursday, hitting $25.06. 34,540,022 shares of the company traded hands, compared to its average volume of 38,472,801. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50-day moving average price of $28.28 and a 200 day moving average price of $28.58. The firm has a market cap of $142.03 billion, a P/E ratio of 33.87, a P/E/G ratio of 0.80 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. Pfizer's quarterly revenue was up 31.2% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.70%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer's payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.